Suppliers / Square Pharmaceuticals

Square Pharmaceuticals

Bangladesh 2 duplicate records merged Updated 9 July 2026

Square Pharmaceuticals is a finished-dose manufacturer based in Bangladesh. It appears in 86 regulatory filings across 9 regulators, without an active US DMF or CEP on file. Its filings concentrate with MINSA (CR), TMDA (TZ) and ZAMRA (ZM). Its GMP standing is certified by ANVISA (Brazil), PPB (KE) and MHRA (UK), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 28 January 2020 as VAI.

0
active US DMFs
0
valid CEPs
4
registered plants 1 with an FDA FEI number
86
filings across 9 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 28 January 2020 VAI US FDA
  • 30 January 2015 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
GAZIPUR, Bangladesh Not on file
GAZIPUR, Bangladesh Not on file
Bangladesh, Bangladesh 3003670128
Machakos, Kenya Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 43 None
TMDA (TZ) 24 None
ZAMRA (ZM) 7 None
US FDA 5 None
RAMA (GE) 2 None
UZPHARM (UZ) 2 None
ANVISA (Brazil) None 2
PPB (KE) None 1
MHRA (UK) None 1
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Square Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 January 2020.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates